American Journal of Respiratory Medicine

, Volume 1, Issue 3, pp 185–193

Biology and Therapeutic Potential of the Interleukin-4/Interleukin-13 Signaling Pathway in Asthma

Leading Article

Abstract

The future management of patients with allergic asthma is poised to change in the coming one to two decades. This prediction is based on fundamental new insights into the pathogenesis of disease, gained through the study of both humans and experimental models of asthma. These studies have revealed that allergic asthma is an immune-mediated disease which, despite the redundancy characteristic of all immune responses, may be induced through a single dominant signaling cascade called the interleukin (IL)-4/IL-13 signaling pathway. In addition to the cytokine IL-4, this pathway includes IL-13, the cytokine receptor subunit IL-4 receptor α (IL-4Rα), Janus-associated tyrosine kinases and the transcription factor, signal transducer and activator of transcription 6. The IL-4 signaling pathway controls the most important cellular developmental (afferent) events that underlie asthma. These include T helper (Th) type 2 cell activation, B cell activation and immunoglobulin (Ig) E secretion, mast cell development, and effector (efferent) events related exclusively to immune effects on the lung such as goblet cell metaplasia and airway hyperresponsiveness. Any of the IL-4 signaling molecules are potentially amenable to pharmacological intervention, but a detailed understanding of the entire pathway is required to appreciate their actual potential for drug development. For example, neutralization strategies that target only IL-4 are unlikely to succeed because they leave IL-13 free to continue the signaling cascade. In contrast, neutralization of IL-4Rα may represent a more feasible strategy, as it should prevent signaling by both IL-4 and IL-13. The therapeutic potential of targeting intracytoplasmic tyrosine kinases has already been achieved with the use of small molecules, suggesting that this approach may be realistically adopted for the treatment of asthma. However, well designed asthma clinical trials are warranted to determine with certainty, the efficacy of therapies based on IL-4/IL-13 blockade.

References

  1. 1.
    Molfino NA, Nannini LJ, Martelli AN, et al. Respiratory arrest in near-fatal asthma. N Engl J Med 1991; 324(5): 285–8PubMedCrossRefGoogle Scholar
  2. 2.
    Van Schayck CP, Dompeling E, Van Herwaarden CL, et al. Interacting effects of atopy and bronchial hyperresponsiveness on the annual decline in lung function and the exacerbation rate in asthma. Am Rev Respir Dis 1991; 144(6): 1297–301PubMedGoogle Scholar
  3. 3.
    Pare PD, Bai TR, Roberts CR. The structural and functional consequences of chronic allergic inflammation of the airways. Ciba Found Symp 1997; 206: 71–86; discussion 86-9, 106-10PubMedGoogle Scholar
  4. 4.
    Brown PJ, Greville HW, Finucane KE. Asthma and irreversible airflow obstruction. Thorax 1984; 39(2): 131–6PubMedCrossRefGoogle Scholar
  5. 5.
    Backman KS, Greenberger PA, Patterson R. Airways obstruction in patients with long-term asthma consistent with ‘irreversible asthma’. Chest 1997; 112(5): 1234–40PubMedCrossRefGoogle Scholar
  6. 6.
    Corry DB, Kheradmand F. Induction and regulation of the IgE response. Nature 1999; 402(6760 Suppl.): B18–23PubMedCrossRefGoogle Scholar
  7. 7.
    Kidney JC, Wong AG, Efthimiadis A, et al. Elevated B cells in sputum of asthmatics. Close correlation with eosinophils. Am J Respir Crit Care Med 1996; 153(2): 540–4PubMedGoogle Scholar
  8. 8.
    Robinson DS, Hamid Q, Ying S, et al. Predominant TH2-like bronchoalveolar T-lymphocyte population in atopic asthma. N Engl J Med 1992; 326(5): 298–304PubMedCrossRefGoogle Scholar
  9. 9.
    Synek M, Beasley R, Frew AJ, et al. Cellular infiltration of the airways in asthma of varying severity. Am J Respir Crit Care Med 1996; 154(1): 224–30PubMedGoogle Scholar
  10. 10.
    Kraft M, Djukanovic R, Wilson S, et al. Alveolar tissue inflammation in asthma. Am J Respir Crit Care Med 1996; 154(5): 1505–10PubMedGoogle Scholar
  11. 11.
    Ying S, Humbert M, Barkans J, et al. Expression of IL-4 and IL-5 mRNA and protein product by CD4+ and CD8+ T cells, eosinophils, and mast cells in bronchial biopsies obtained from atopic and nonatopic (intrinsic) asthmatics. J Immunol 1997; 158(7): 3539–44PubMedGoogle Scholar
  12. 12.
    Humbert M, Durham SR, Ying S, et al. IL-4 and IL-5 mRNA and protein in bronchial biopsies from patients with atopic and nonatopic asthma: evidence against ‘intrinsic’ asthma being a distinct immunopathologic entity. Am J Respir Crit Care Med 1996; 154(5): 1497–504PubMedGoogle Scholar
  13. 13.
    Gratziou C, Carroll M, Montefort S, et al. Inflammatory and T-cell profile of asthmatic airways 6 hours after local allergen provocation. Am J Respir Crit Care Med 1996; 153(2): 515–20PubMedGoogle Scholar
  14. 14.
    Bradley BL, Azzawi M, Jacobson M, et al. Eosinophils, T-lymphocytes, mast cells, neutrophils, and macrophages in bronchial biopsy specimens from atopic subjects with asthma: comparison with biopsy specimens from atopic subjects without asthma and normal control subjects and relationship to bronchial hyperresponsiveness. J Allergy Clin Immunol 1991; 88(4): 661–74PubMedCrossRefGoogle Scholar
  15. 15.
    Shimura S, Andoh Y, Haraguchi M, et al. Continuity of airway goblet cells and intraluminal mucus in the airways of patients with bronchial asthma. Eur Respir J 1996; 9(7): 1395–401PubMedCrossRefGoogle Scholar
  16. 16.
    Aikawa T, Shimura S, Sasaki H, et al. Marked goblet cell hyperplasia with mucus accumulation in the airways of patients who died of severe acute asthma attack. Chest 1992; 101(4): 916–21PubMedCrossRefGoogle Scholar
  17. 17.
    Hogg JC. The pathology of asthma. APMIS 1997; 105(10): 735–45PubMedCrossRefGoogle Scholar
  18. 18.
    Busse WW, Coffman RL, Gelfand EW, et al. Mechanisms of persistent airway inflammation in asthma. A role for T cells and T-cell products. Am J Respir Crit Care Med 1995; 152(1): 388–93PubMedGoogle Scholar
  19. 19.
    Krinzman SJ, De Sanctis GT, Cernadas M, et al. Inhibition of T cell costimulation abrogates airway hyperresponsiveness in a murine model. J Clin Invest 1996; 98(12): 2693–9PubMedCrossRefGoogle Scholar
  20. 20.
    Van Oosterhout AJ, Hofstra CL, Shields R, et al. Murine CTLA4-IgG treatment inhibits airway eosinophilia and hyperresponsiveness and attenuates IgE up-regulation in a murine model of allergic asthma. Am J Respir Cell Mol Biol 1997; 17(3): 386–92PubMedGoogle Scholar
  21. 21.
    Gavett SH, Chen X, Finkelman F, et al. Depletion of murine CD4+ T lymphocytes prevents antigen-induced airway hyperreactivity and pulmonary eosinophilia. Am J Respir Cell Mol Biol 1994; 10: 587–93PubMedGoogle Scholar
  22. 22.
    Corry DB, Folkesson HG, Warnock ML, et al. Interleukin 4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity. J Exp Med 1996; 183(1): 109–17PubMedCrossRefGoogle Scholar
  23. 23.
    Corry DB, Grunig G, Hadeiba H, et al. Requirements for allergen-induced airway hyperreactivity in T and B cell-deficient mice. Mol Med 1998; 4(5): 344–55PubMedGoogle Scholar
  24. 24.
    Watanabe A, Mishima H, Kotsimbos TC, et al. Adoptively transferred late allergic airway responses are associated with Th2-type cytokines in the rat. Am J Respir Cell Mol Biol 1997; 16(1): 69–74PubMedGoogle Scholar
  25. 25.
    Grunig G, Warnock M, Wakil AE, et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 1998; 282(5397): 2261–3PubMedCrossRefGoogle Scholar
  26. 26.
    Madden KB, Urban Jr JF, Ziltener HJ, et al. Antibodies to IL-3 and IL-4 suppress helminth-induced intestinal mastocytosis. J Immunol 1991; 147(4): 1387–91PubMedGoogle Scholar
  27. 27.
    Finkelman FD, Katona IM, Urban Jr JF, et al. IL-4 is required to generate and sustain in vivo IgE responses. J Immunol 1988; 141(7): 2335–41PubMedGoogle Scholar
  28. 28.
    Snapper CM, Finkelman FD, Paul WE. Differential regulation of IgG1 and IgE synthesis by interleukin 4. J Exp Med 1988; 167(1): 183–96PubMedCrossRefGoogle Scholar
  29. 29.
    Finkelman FD, Katona IM, Urban Jr JF, et al. Control of in vivo IgE production in the mouse by interleukin 4. Ciba Found Symp 1989; 147: 3–17; discussion 17-22PubMedGoogle Scholar
  30. 30.
    Coffman RL, Seymour BW, Hudak S, et al. Antibody to interleukin-5 inhibits helminth-induced eosinophilia in mice. Science 1989; 245(4915): 308–10PubMedCrossRefGoogle Scholar
  31. 31.
    Wills-Karp M, Luyimbazi J, Xu X, et al. Interleukin-13: central mediator of allergic asthma. Science 1998; 282(5397): 2258–61PubMedCrossRefGoogle Scholar
  32. 32.
    Obiri NI, Debinski W, Leonard WJ, et al. Receptor for interleukin 13. Interaction with interleukin 4 by a mechanism that does not involve the common gamma chain shared by receptors for interleukins 2, 4, 7, 9, and 15. J Biol Chem 1995; 270(15): 8797–804PubMedCrossRefGoogle Scholar
  33. 33.
    Lefort S, Vita N, Reeb R, et al. IL-13 and IL-4 share signal transduction elements as well as receptor components in TF-1 cells. FEBS Lett 1995; 366(2-3): 122–6PubMedCrossRefGoogle Scholar
  34. 34.
    Smerz-Bertling C, Duschl A. Both interleukin 4 and interleukin 13 induce tyrosine phosphorylation of the 140-kDa subunit of the interleukin 4 receptor. J Biol Chem 1995; 270(2): 966–70PubMedCrossRefGoogle Scholar
  35. 35.
    Murata T, Puri RK. Comparison of IL-13- and IL-4-induced signaling in EBV-immortalized human B cells. Cell Immunol 1997; 175(1): 33–40PubMedCrossRefGoogle Scholar
  36. 36.
    Orchansky PL, Ayres SD, Hilton DJ, et al. An interleukin (IL)-13 receptor lacking the cytoplasmic domain fails to transduce IL-13-induced signals and inhibits responses to IL-4. J Biol Chem 1997; 272(36): 22940–7PubMedCrossRefGoogle Scholar
  37. 37.
    Palmer-Crocker RL, Hughes CC, Pober JS. IL-4 and IL-13 activate the JAK2 tyrosine kinase and Stat6 in cultured human vascular endothelial cells through a common pathway that does not involve the gamma c chain. J Clin Invest 1996; 98(3): 604–9PubMedCrossRefGoogle Scholar
  38. 38.
    Kopf M, Le GG, Bachmann M, et al. Disruption of the murine IL-4 gene blocks Th2 cytokine responses. Nature 1993; 362(6417): 245–8PubMedCrossRefGoogle Scholar
  39. 39.
    Webb DC, McKenzie AN, Koskinen AM, et al. Integrated signals between IL-13, IL-4, and IL-5 regulate airways hyperreactivity. J Immunol 2000; 165(1): 108–13PubMedGoogle Scholar
  40. 40.
    Blease K, Jakubzick C, Westwick J, et al. Therapeutic effect of IL-13 immunoneutralization during chronic experimental fungal asthma. J Immunol 2001; 166(8): 5219–24PubMedGoogle Scholar
  41. 41.
    Kamogawa Y, Minasi LE, Carding SR, et al. The relationship of IL-4- and IFNg-producing T cells studied by lineage ablation of IL-4-producing cells. Cell 1993; 75: 985–95PubMedCrossRefGoogle Scholar
  42. 42.
    Noben-Trauth N, Shultz LD, Brombacher F, et al. An interleukin 4 (IL-4)-independent pathway for CD4+ T cell IL-4 production is revealed in IL-4 receptor-deficient mice. Proc Natl Acad Sci U S A 1997; 94(20): 10838–43PubMedCrossRefGoogle Scholar
  43. 43.
    Dent AL, Hu-Li J, Paul WE, et al. T helper type 2 inflammatory disease in the absence of interleukin 4 and transcription factor STAT6. Proc Natl Acad Sci U S A 1998; 95(23): 13823–8PubMedCrossRefGoogle Scholar
  44. 44.
    Gauchat JF, Schlagenhauf E, Feng NP, et al. A novel 4-kb interleukin-13 receptor alpha mRNA expressed in human B, T, and endothelial cells encoding an alternate type-II interleukin-4/interleukin-13 receptor. Eur J Immunol 1997; 27(4): 971–8PubMedCrossRefGoogle Scholar
  45. 45.
    Kaplan MH, Schindler U, Smiley ST, et al. Stat6 is required for mediating responses to IL-4 and for development of Th2 cells. Immunity 1996; 4(3): 313–9PubMedCrossRefGoogle Scholar
  46. 46.
    Hoshino T, Winkler-Pickett RT, Mason AT, et al. IL-13 production by NK cells: IL-13-producing NK and T cells are present in vivo in the absence of IFN-gamma. J Immunol 1999; 162(1): 51–9PubMedGoogle Scholar
  47. 47.
    Burd PR, Thompson WC, Max EE, et al. Activated mast cells produce interleukin 13. J Exp Med 1995; 181(4): 1373–80PubMedCrossRefGoogle Scholar
  48. 48.
    Hancock A, Armstrong L, Gama R, et al. Production of interleukin 13 by alveolar macrophages from normal and fibrotic lung. Am J Respir Cell Mol Biol 1998; 18(1): 60–5PubMedGoogle Scholar
  49. 49.
    McKenzie GJ, Emson CL, Bell SE, et al. Impaired development of Th2 cells in IL-13-deficient mice. Immunity 1998; 9(3): 423–32PubMedCrossRefGoogle Scholar
  50. 50.
    Walter DM, Mcintire JJ, Berry G, et al. Critical role for IL-13 in the development of allergen-induced airway hyperreactivity. J Immunol 2001; 167: 4668–75PubMedGoogle Scholar
  51. 51.
    Zurawski G, deVries JE. Interleukin 13, an interleukin 4-like cytokine that acts on monocytes and B cells, but not on T cells. Immunol Today 1994; 15(1): 19–26PubMedCrossRefGoogle Scholar
  52. 52.
    Hilton DJ, Zhang JG, Metcalf D, et al. Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor. Proc Natl Acad Sci U S A 1996; 93(1): 497–501PubMedCrossRefGoogle Scholar
  53. 53.
    Donaldson DD, Whitters MJ, Fitz L, et al. The murine IL-13Ra2: molecular cloning, characterization and comparison with murine IL-13Ra1. J Immunol 1998; 161(5): 2317–24PubMedGoogle Scholar
  54. 54.
    Shimoda K, van Deursen J, Sangster MY, et al. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat6 gene. Nature 1996; 380(6575): 630–3PubMedCrossRefGoogle Scholar
  55. 55.
    Kuhn R, Rajewsky K, Muller W. Generation and analysis of interleukin-4 deficient mice. Science 1991; 254(5032): 707–10PubMedCrossRefGoogle Scholar
  56. 56.
    Grunewald SM, Werthmann A, Schnarr B, et al. An antagonistic IL-4 mutant prevents type I allergy in the mouse: inhibition of the IL-4/IL-13 receptor system completely abrogates humoral immune response to allergen and development of allergic symptoms in vivo. J Immunol 1998; 160(8): 4004–9PubMedGoogle Scholar
  57. 57.
    Morawetz RA, Gabriele L, Rizzo LV, et al. Interleukin (IL)-4-independent immunoglobulin class switch to immunoglobulin (Ig)E in the mouse. J Exp Med 1996; 184(5): 1651–61PubMedCrossRefGoogle Scholar
  58. 58.
    Emson CL, Bell SE, Jones A, et al. Interleukin (IL)-4-independent induction of immunoglobulin (Ig)E, and perturbation of T cell development in transgenic mice expressing IL-13. J Exp Med 1998; 188(2): 399–404PubMedCrossRefGoogle Scholar
  59. 59.
    McKenzie GJ, Fallon PG, Emson CL, et al. Simultaneous disruption of interleukin (IL)-4 and IL-13 defines individual roles in T helper cell type 2-mediated responses. J Exp Med 1999; 189(10): 1565–72PubMedCrossRefGoogle Scholar
  60. 60.
    Chiaramonte MG, Schopf LR, Neben TY, et al. IL-13 is a key regulatory cytokine for Th2 cell-mediated pulmonary granuloma formation and IgE responses induced by Schistosoma mansoni eggs. J Immunol 1999; 162(2): 920–30PubMedGoogle Scholar
  61. 61.
    Newlands GF, Miller HR, MacKellar A, et al. Stem cell factor contributes to intestinal mucosal mast cell hyperplasia in rats infected with Nippostrongylus brasiliensis or Trichinella spiralis, but anti-stem cell factor treatment decreases parasite egg production during N brasiliensis infection. Blood 1995; 86(5): 1968–76PubMedGoogle Scholar
  62. 62.
    Townsend JM, Fallon GP, Matthews JD, et al. IL-9-deficient mice establish fundamental roles for IL-9 in pulmonary mastocytosis and goblet cell hyperplasia but not T cell development. Immunity 2000; 13(4): 573–83PubMedCrossRefGoogle Scholar
  63. 63.
    Temann UA, Geba GP, Rankin JA, et al. Expression of interleukin 9 in the lungs of transgenic mice causes airway inflammation, mast cell hyperplasia, and bronchial hyperresponsiveness. J Exp Med 1998; 188(7): 1307–20PubMedCrossRefGoogle Scholar
  64. 64.
    Renauld JC, Kermouni A, Vink A, et al. Interleukin-9 and its receptor: involvement in mast cell differentiation and T cell oncogenesis. J Leukoc Biol 1995; 57(3): 353–60PubMedGoogle Scholar
  65. 65.
    Nilsson G, Nilsson K. Effects of interleukin (IL)-13 on immediate-early response gene expression, phenotype and differentiation of human mast cells. Comparison with IL-4. Eur J Immunol 1995; 25(3): 870–3PubMedCrossRefGoogle Scholar
  66. 66.
    Seder RA, Paul WE, Ben SS, et al. Production of interleukin-4 and other cytokines following stimulation of mast cell lines and in vivo mast cells/basophils. Int Arch Allergy Appl Immunol 1991; 94(1-4): 137–40PubMedCrossRefGoogle Scholar
  67. 67.
    Bradding P, Roberts JA, Britten KM, et al. Interleukin-4, -5, and -6 and tumor necrosis factor-alpha in normal and asthmatic airways: evidence for the human mast cell as a source of these cytokines. Am J Respir Cell Mol Biol 1994; 10(5): 471–80PubMedGoogle Scholar
  68. 68.
    Bradding P, Feather IH, Howarth PH, et al. Interleukin 4 is localized to and released by human mast cells. J Exp Med 1992; 176(5): 1381–6PubMedCrossRefGoogle Scholar
  69. 69.
    Hogan SP, Mould A, Kikutani H, et al. Aeroallergen-induced eosinophilic inflammation, lung damage, and airways hyperreactivity in mice can occur independently of IL-4 and allergen-specific immunoglobulins. J Clin Invest 1997; 99(6): 1329–39PubMedCrossRefGoogle Scholar
  70. 70.
    Brusselle G, Kips J, Joos G, et al. Allergen-induced airway inflammation and bronchial responsiveness in wild-type and interleukin-4-deficient mice. Am J Respir Cell Mol Biol 1995; 12(3): 254–9PubMedGoogle Scholar
  71. 71.
    Hogan SP, Matthaei KI, Young JM, et al. A novel T cell-regulated mechanism modulating allergen-induced airways hyperreactivity in BALB/c mice independently of IL-4 and IL-5. J Immunol 1998; 161: 1501–9PubMedGoogle Scholar
  72. 72.
    Cohn L, Tepper JS, Bottomly K. IL-4-independent induction of airway hyperresponsiveness by Th2, but not Th1, cells. J Immunol 1998; 161: 3813–6PubMedGoogle Scholar
  73. 73.
    Corry DB. IL-13 in allergy: home at last. Curr Opin Immunol 1999; 11(6): 610–4PubMedCrossRefGoogle Scholar
  74. 74.
    Nelms K, Keegan AD, Zamorano J, et al. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 1999; 17: 701–38PubMedCrossRefGoogle Scholar
  75. 75.
    Chomarat P, Banchereau J. An update on interleukin-4 and its receptor. Eur Cytokine Netw 1997; 8(4): 333–44PubMedGoogle Scholar
  76. 76.
    Miloux B, Laurent P, Bonnin O, et al. Cloning of the human IL-13R alpha1 chain and reconstitution with the IL4R alpha of a functional IL-4/IL-13 receptor complex. FEBS Lett 1997; 401(2-3): 163–6PubMedCrossRefGoogle Scholar
  77. 77.
    Callard RE, Matthews DJ, Hibbert L. IL-4 and IL-13 receptors: are they one and the same? Immunol Today 1996; 17(3): 108–10PubMedCrossRefGoogle Scholar
  78. 78.
    Kotowicz K, Callard RE, Friedrich K, et al. Biological activity of IL-4 and IL-13 on human endothelial cells: functional evidence that both cytokines act through the same receptor. Int Immunol 1996; 8(12): 1915–25PubMedCrossRefGoogle Scholar
  79. 79.
    Murata T, Obiri NI, Puri RK. Human ovarian-carcinoma cell lines express IL-4 and IL-13 receptors: comparison between IL-4- and IL-13-induced signal transduction. Int J Cancer 1997; 70(2): 230–40PubMedCrossRefGoogle Scholar
  80. 80.
    Murata T, Obiri NI, Debinski W, et al. Structure of IL-13 receptor: analysis of subunit composition in cancer and immune cells. Biochem Biophys Res Commun 1997; 238(1): 90–4PubMedCrossRefGoogle Scholar
  81. 81.
    Murata T, Noguchi PD, Puri RK. IL-13 induces phosphorylation and activation of JAK2 Janus kinase in human colon carcinoma cell lines: similarities between IL-4 and IL-13 signaling. J Immunol 1996; 156(8): 2972–8PubMedGoogle Scholar
  82. 82.
    Murata T, Taguchi J, Puri RK. Interleukin-13 receptor alpha’ but not alpha chain: a functional component of interleukin-4 receptors. Blood 1998; 91(10): 3884–91PubMedGoogle Scholar
  83. 83.
    Obiri NI, Murata T, Debinski W, et al. Modulation of interleukin (IL)-13 binding and signaling by the gammac chain of the IL-2 receptor. J Biol Chem 1997; 272(32): 20251–8PubMedCrossRefGoogle Scholar
  84. 84.
    Obiri NI, Leland P, Murata T, et al. The IL-13 receptor structure differs on various cell types and may share more than one component with IL-4 receptor. J Immunol 1997; 158(2): 756–64PubMedGoogle Scholar
  85. 85.
    Vita N, Lefort S, Laurent P, et al. Characterization and comparison of the interleukin 13 receptor with the interleukin 4 receptor on several cell types. J Biol Chem 1995; 270(8): 3512–7PubMedCrossRefGoogle Scholar
  86. 86.
    Zhang JG, Hilton DJ, Willson TA, et al. Identification, purification, and characterization of a soluble interleukin (IL)-13-binding protein: evidence that it is distinct from the cloned Il-13 receptor and Il-4 receptor alpha-chains. J Biol Chem 1997; 272(14): 9474–80PubMedCrossRefGoogle Scholar
  87. 87.
    Gavett SH, O’Hearn DJ, Karp CL, et al. Interleukin-4 receptor blockade prevents airway responses induced by antigen challenge in mice. Am J Physiol 1997; 272 (2 Pt 1): L253–61PubMedGoogle Scholar
  88. 88.
    Malabarba MG, Rui H, Deutsch HH, et al. Interleukin-13 is a potent activator of JAK3 and STAT6 in cells expressing interleukin-2 receptor-gamma and interleukin-4 receptor-alpha. Biochem J 1996; 319 (Pt 3): 865–72PubMedGoogle Scholar
  89. 89.
    van der Pouw Kraan TC, van Veen A, Boeije LC, et al. An IL-13 promoter polymorphism associated with increased risk of allergic asthma. Genes Immun 1999; 1(1): 61–5PubMedCrossRefGoogle Scholar
  90. 90.
    Suzuki I, Hizawa N, Yamaguchi E, et al. Association between a C+33T polymorphism in the IL-4 promoter region and total serum IgE levels. Clin Exp Allergy 2000; 30(12): 1746–9PubMedCrossRefGoogle Scholar
  91. 91.
    Graves PE, Kabesch M, Halonen M, et al. A cluster of seven tightly linked polymorphisms in the IL-13 gene is associated with total serum IgE levels in three populations of white children. J Allergy Clin Immunol 2000; 105(3): 506–13PubMedCrossRefGoogle Scholar
  92. 92.
    Chouchane L, Sfar I, Bousaffara R, et al. A repeat polymorphism in interleukin-4 gene is highly associated with specific clinical phenotypes of asthma. Int Arch Allergy Immunol 1999; 120(1): 50–5PubMedCrossRefGoogle Scholar
  93. 93.
    Hershey GK, Friedrich MF, Esswein LA, et al. The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor. N Engl J Med 1997; 337(24): 1720–5PubMedCrossRefGoogle Scholar
  94. 94.
    Mitsuyasu H, Izuhara K, Mao XQ, et al. Ile50Val variant of IL4R alpha upregulates IgE synthesis and associates with atopic asthma. Nat Genet 1998; 19(2): 119–20PubMedCrossRefGoogle Scholar
  95. 95.
    Mitsuyasu H, Yanagihara Y, Mao XQ, et al. Cutting edge: dominant effect of Ile50Val variant of the human IL-4 receptor alpha-chain in IgE synthesis. J Immunol 1999; 162(3): 1227–31PubMedGoogle Scholar
  96. 96.
    Borish LC, Nelson HS, Corren J, et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J Allergy Clin Immunol 2001; 107(6): 963–70PubMedCrossRefGoogle Scholar
  97. 97.
    Russell SM, Johnston JA, Noguchi M, et al. Interaction of IL-2R beta and gamma c chains with Jak1 and Jak3: implications for XSCID and XCID. Science 1994; 266(5187): 1042–5PubMedCrossRefGoogle Scholar
  98. 98.
    Thomis DC, Berg LJ. Peripheral expression of Jak3 is required to maintain T lymphocyte function. J Exp Med 1997; 185(2): 197–206PubMedCrossRefGoogle Scholar
  99. 99.
    Oakes SA, Candotti F, Johnston JA, et al. Signaling via IL-2 and IL-4 in JAK3-deficient severe combined immunodeficiency lymphocytes: JAK3-dependent and independent pathways. Immunity 1996; 5(6): 605–15PubMedCrossRefGoogle Scholar
  100. 100.
    Wang LH, Kirken RA, Yang XY, et al. Selective disruption of interleukin 4 autocrine-regulated loop by a tyrosine kinase inhibitor restricts activity of T-helper 2 cells. Blood 2000; 95(12): 3816–22PubMedGoogle Scholar
  101. 101.
    Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med 2001; 344(14): 1038–42PubMedCrossRefGoogle Scholar
  102. 102.
    Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344(14): 1031–7PubMedCrossRefGoogle Scholar
  103. 103.
    Weller PF, Plaut M, Taggart V, et al. The relationship of asthma therapy and Churg-Strauss syndrome: NIH workshop summary report. J Allergy Clin Immunol 2001; 108(2): 175–83PubMedCrossRefGoogle Scholar

Copyright information

© Adis International Limited 2002

Authors and Affiliations

  1. 1.Departments of Medicine and the Biology of Inflammation CenterBaylor College of MedicineHoustonUSA
  2. 2.Department of ImmunologyBaylor College of MedicineHoustonUSA
  3. 3.Medicine/Pulmonary SectionBaylor College of MedicineHoustonUSA

Personalised recommendations